DrugPatentWatch Database Preview

Ucb Inc Company Profile

« Back to Dashboard

What is the competitive landscape for UCB INC, and when can generic versions of UCB INC drugs launch?

UCB INC has thirty-nine approved drugs.

There are fifteen US patents protecting UCB INC drugs.

Summary for Ucb Inc

US Patents:	15
Tradenames:	26
Ingredients:	21
NDAs:	39
Drug Master File Entries:	1
Patent Litigation for Ucb Inc:	See patent lawsuits for Ucb Inc

Drugs and US Patents for Ucb Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-002	Oct 30, 2003		DISCN	No	No	6,024,981		Y
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-004	May 12, 2016		RX	Yes	No
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-005	May 12, 2016		RX	Yes	Yes	6,911,461		Y	Y
Ucb Inc	ALBUTEROL SULFATE	albuterol sulfate	TABLET;ORAL	073121-001	Sep 29, 1992		DISCN	No	No

Expired US Patents for Ucb Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	TUSSIONEX PENNKINETIC	chlorpheniramine polistirex; hydrocodone polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	019111-001	Dec 31, 1987	4,221,778
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-003	Nov 30, 1999	4,837,223
Ucb Inc	UNIRETIC	hydrochlorothiazide; moexipril hydrochloride	TABLET;ORAL	020729-001	Jun 27, 1997	4,344,949
Ucb Inc	FLUXID	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	021712-002	Sep 24, 2004	6,024,981

Paragraph IV (Patent) Challenges for UCB INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Transdermal Film	1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr		2013-11-26
	Oral Solution	10 mg/mL		2012-10-29
	Injection	10 mg/mL, 20 mL		2016-06-30
	Orally Disintegrating Tablets	0.25 mg, 0.5 mg, 1 mg and 2 mg		2005-12-27
	Tablets	1000 mg		2007-01-24
	Tablets	50 mg, 100 mg, 150 mg, and 200 mg		2012-10-29
	Extended-release Tablets	1000 mg		2011-01-07
	Tablets	7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg		2004-01-15

Non-Orange Book US Patents for Ucb Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,713,635	2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
7,217,826	2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
6,969,770	2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
6,048,899	Anticonvulsant enantiomeric amino acid derivatives

International Patents for Ucb Inc Drugs

Country	Document Number	Estimated Expiration
Romania	121559
China	101953819
Hungary	226733
Japan	4837916

Supplementary Protection Certificates for Ucb Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
/2006	Austria		PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 - EU/1/05/331/013 20060215
C0025	France		PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 20060215
2006 00020	Denmark		PRODUCT NAME: ROTIGOTINE
24/2006	Austria		PRODUCT NAME: ROTIGOTINE

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Ucb Inc